AveXis, Inc. (NASDAQ:AVXS) has been assigned a consensus rating of “Buy” from the ten analysts that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $94.33.

A number of equities research analysts have recently issued reports on the stock. UBS AG assumed coverage on shares of AveXis in a report on Wednesday, March 29th. They issued a “buy” rating and a $95.00 target price on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $92.00 target price on shares of AveXis in a report on Thursday, May 25th. Chardan Capital set a $103.00 target price on shares of AveXis and gave the company a “buy” rating in a report on Sunday, June 18th. Citigroup Inc. assumed coverage on shares of AveXis in a report on Tuesday, May 23rd. They issued a “buy” rating and a $90.00 target price on the stock. Finally, Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday.

WARNING: “AveXis, Inc. (AVXS) Given Average Rating of “Buy” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/07/17/avexis-inc-avxs-given-average-rating-of-buy-by-brokerages.html.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $81.88, for a total value of $145,746.40. Following the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $145,746.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders sold 5,340 shares of company stock worth $416,840. Insiders own 18.60% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. bought a new position in AveXis during the first quarter valued at $297,000. Swiss National Bank boosted its position in AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock valued at $2,083,000 after buying an additional 800 shares in the last quarter. Pictet Asset Management Ltd. boosted its position in AveXis by 44.9% in the first quarter. Pictet Asset Management Ltd. now owns 153,606 shares of the company’s stock valued at $11,679,000 after buying an additional 47,588 shares in the last quarter. Bank of New York Mellon Corp boosted its position in AveXis by 27.8% in the first quarter. Bank of New York Mellon Corp now owns 62,922 shares of the company’s stock valued at $4,784,000 after buying an additional 13,691 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in AveXis by 30.2% in the first quarter. Russell Investments Group Ltd. now owns 17,550 shares of the company’s stock valued at $1,335,000 after buying an additional 4,067 shares in the last quarter. 90.55% of the stock is currently owned by hedge funds and other institutional investors.

AveXis (NASDAQ:AVXS) traded up 0.89% during trading on Monday, reaching $81.72. The company’s stock had a trading volume of 170,366 shares. The company’s market cap is $2.27 billion. The company’s 50 day moving average price is $73.90 and its 200 day moving average price is $66.54. AveXis has a 52 week low of $31.55 and a 52 week high of $85.98.

AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, May 11th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.13. During the same quarter in the prior year, the company earned ($1.24) EPS. On average, equities analysts anticipate that AveXis will post ($4.43) earnings per share for the current fiscal year.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.